WO1998020146A3 - Stabilized transient gene expression - Google Patents

Stabilized transient gene expression Download PDF

Info

Publication number
WO1998020146A3
WO1998020146A3 PCT/US1997/019860 US9719860W WO9820146A3 WO 1998020146 A3 WO1998020146 A3 WO 1998020146A3 US 9719860 W US9719860 W US 9719860W WO 9820146 A3 WO9820146 A3 WO 9820146A3
Authority
WO
WIPO (PCT)
Prior art keywords
gene expression
transient gene
cells
transient expression
stabilized
Prior art date
Application number
PCT/US1997/019860
Other languages
French (fr)
Other versions
WO1998020146A2 (en
Inventor
Randal A Goffe
Adeelia S Goffe
Original Assignee
Genespan Corp
Randal A Goffe
Adeelia S Goffe
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genespan Corp, Randal A Goffe, Adeelia S Goffe filed Critical Genespan Corp
Priority to JP10521611A priority Critical patent/JP2000509998A/en
Priority to EP97946432A priority patent/EP0941356A2/en
Priority to AU51601/98A priority patent/AU732445B2/en
Priority to CA002270137A priority patent/CA2270137A1/en
Publication of WO1998020146A2 publication Critical patent/WO1998020146A2/en
Priority to US09/093,449 priority patent/US6146847A/en
Publication of WO1998020146A3 publication Critical patent/WO1998020146A3/en
Priority to US10/047,649 priority patent/US20030073654A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/131—Amines acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation

Abstract

This invention provides methods and agents for enhancing transient expression in eukaryotic cells. Also provided are a model system for achieving prolonged transient expression in solid tumors, a means for culturing hepatocytes without feeder cells or an extracellular matrix bonded to the substratum, and a mehtod for manipulating cellular metabolism to reduce the cells' consumption of glucose.
PCT/US1997/019860 1996-11-01 1997-10-31 Stabilized transient gene expression WO1998020146A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
JP10521611A JP2000509998A (en) 1996-11-01 1997-10-31 Stabilized transient gene expression
EP97946432A EP0941356A2 (en) 1996-11-01 1997-10-31 Stabilized transient gene expression
AU51601/98A AU732445B2 (en) 1996-11-01 1997-10-31 Stabilized transient gene expression
CA002270137A CA2270137A1 (en) 1996-11-01 1997-10-31 Stabilized transient gene expression
US09/093,449 US6146847A (en) 1996-11-01 1998-06-08 Stabilized transient gene expression
US10/047,649 US20030073654A1 (en) 1996-11-01 2002-01-16 Stabilized transient gene expression

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US3010996P 1996-11-01 1996-11-01
US60/030,109 1996-11-01
US83374797A 1997-04-11 1997-04-11
US08/833,747 1997-04-11

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US83374797A Continuation-In-Part 1996-11-01 1997-04-11

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US09/093,449 Continuation-In-Part US6146847A (en) 1996-11-01 1998-06-08 Stabilized transient gene expression

Publications (2)

Publication Number Publication Date
WO1998020146A2 WO1998020146A2 (en) 1998-05-14
WO1998020146A3 true WO1998020146A3 (en) 1998-08-20

Family

ID=26705677

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/019860 WO1998020146A2 (en) 1996-11-01 1997-10-31 Stabilized transient gene expression

Country Status (6)

Country Link
EP (1) EP0941356A2 (en)
JP (1) JP2000509998A (en)
CN (1) CN1238807A (en)
AU (1) AU732445B2 (en)
CA (1) CA2270137A1 (en)
WO (1) WO1998020146A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102533722B (en) * 2010-12-24 2014-03-12 北京义翘神州生物技术有限公司 Method for improving transient expression of recombinant proteins in mammalian cells through temperature jump
CN106811483B (en) * 2017-02-16 2020-04-07 甘肃农业大学 Method for efficiently transfecting eukaryotic cells

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0486917A2 (en) * 1990-11-17 1992-05-27 BEHRINGWERKE Aktiengesellschaft Antiviral activity from the rep gene of adenoassociated virus-2
WO1994016737A1 (en) * 1993-01-26 1994-08-04 Weiner David B Compositions and methods for delivery of genetic material
WO1995026718A1 (en) * 1994-04-01 1995-10-12 Apollon, Inc. Compositions and methods for delivery of genetic material
WO1996023898A1 (en) * 1995-01-31 1996-08-08 Novo Nordisk A/S A method of detecting biologically active substances

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0486917A2 (en) * 1990-11-17 1992-05-27 BEHRINGWERKE Aktiengesellschaft Antiviral activity from the rep gene of adenoassociated virus-2
WO1994016737A1 (en) * 1993-01-26 1994-08-04 Weiner David B Compositions and methods for delivery of genetic material
WO1995026718A1 (en) * 1994-04-01 1995-10-12 Apollon, Inc. Compositions and methods for delivery of genetic material
WO1996023898A1 (en) * 1995-01-31 1996-08-08 Novo Nordisk A/S A method of detecting biologically active substances

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
ANDERSON J.W. & BRIDGES S.R.: "Short-chain fatty acid fermentation products of plant fiber affect glucose metabolism of isolated rat hepatocytes", PRO. SOC. EXP. BIOL. MED., vol. 177, 1984, pages 372 - 376, XP002067120 *
BATTAGLIA C. ET AL: "Structural basis for beta 1 integrin-ediated cell adhesion to a large heparan sulfate proteoglycan from basement membranes", EUR. J. CELL. BIOL., vol. 61, no. 1, June 1993 (1993-06-01), pages 92 - 99, XP002065999 *
BEIS I. & THEOPHILIDIS G.: "Phosphofructokinase in the plerocercoids of S. solidus", INT. J. PARASITOLOGY, vol. 12, no. 5, 1982, pages 389 - 394, XP002054819 *
GOFFE AS & GOFFE RA: "Chemical stabilizingagents for transient DNA in cell culture".163rd AAAS National Meeting and Science Innovation Exposition, Poster A106. Seattle, WA, USA, February 13-18, 1997. *
GOLDSTEIN S. ET AL.: "Enhanced transfection efficiency and improved cell survival after electroporation of G2/M-synchronized cells and treatment with sodium butyrate", NUCL . ACIDS RES., vol. 17, no. 10, 1989, pages 3959 - 3972, XP002054817 *
GORMAN C.M. & HOWARD B.H.: "Expression of recombinant plasmids in mammalian cells is enhanced by sodium butyrate", NUCL. ACIDS RES., vol. 11, no. 21, 1983, pages 7631 - 7648, XP002054816 *
MISLICK K.A. & BALDSCHWIELER J.D.: "Evidence for the role of proteoglycans in cation-mediated gene transfer", PROC. NATL. ACAD. SCI. USA, vol. 93, October 1996 (1996-10-01), pages 12349 - 12354, XP002065997 *
MORAND C. ET AL.: "Importance of the modulation of glycolysis in the control of lactate metabolism by fatty acids in isolated rat hepatocytes from fed rats", ARCH. BIOCHEM. BIOPHYS, vol. 309, no. 2, March 1994 (1994-03-01), pages 254 - 260, XP002067121 *
NORDENBERG J ET AL.: "Inhibition of growth of human melanoma cells and enhancement of alkaline phosphatase", HAREFUAH, vol. 111, no. 1/2, - 1986, pages 59, 21 - 23, XP002065996 *
PIEPKORN M.W. & CHAPMAN D.L.: "Glycosaminoglycans and the substrate attachment of murine myeloma, 3T3 and cutaneous fibrosarcoma cells.", LAB. INVEST., vol. 53, no. 1, July 1985 (1985-07-01), pages 22 - 29, XP002065998 *
SATOH K. ET AL.: "Effect of drugs on gene expression in mammalian cells: a highly efficient procedure to test large numbers of samples", NUCL. ACIDS RES., vol. 21, no. 18, 1993, pages 4429 - 4430, XP002056202 *
WARDEN D ET AL: "INFLUENCE OF DIETHYLAMINOETHYL-DEXTRAN ON UPTAKE AND DEGRADATION OFPOLYOMA VIRUS DEOXYRIBONUCLEIC ACID BY MOUSE EMBRYO CELLS", JOURNAL OF VIROLOGY, vol. 4, no. 4, 1 October 1969 (1969-10-01), pages 380 - 387, XP000569882 *

Also Published As

Publication number Publication date
WO1998020146A2 (en) 1998-05-14
CN1238807A (en) 1999-12-15
JP2000509998A (en) 2000-08-08
CA2270137A1 (en) 1998-05-14
AU732445B2 (en) 2001-04-26
EP0941356A2 (en) 1999-09-15
AU5160198A (en) 1998-05-29

Similar Documents

Publication Publication Date Title
AU2260097A (en) Hematopoietic cell culture nutrient supplement
AU4330597A (en) Serum-free mammalian cell culture medium, and uses thereof
WO2001023592A3 (en) Methods for making recombinant proteins using apoptosis inhibitors
ZA964776B (en) Mammalian cell culture process.
WO2002033047A3 (en) In vitro embryo culture device
HK1026000A1 (en) Method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the same.
CA2323086A1 (en) Regulation of endogenous gene expression in cells using zinc finger proteins
AU2086199A (en) Plant uridine diphosphate-glucose dehydrogenase genes, proteins, and uses thereof
EP1123975A4 (en) Three-dimensional cell incubation media and method for incubating cells by using the same
IL180924A (en) Method for regulating cell proliferation and cell death
DE69617583D1 (en) In vitro cell culture system
CA2146734A1 (en) Method for long term subculture of dermal papilla cells
PL338338A1 (en) Controllable cytolysis of target cells, cytolysis causing media and composition as well as compound suitable for use in obtaining such media
PL336983A1 (en) Compounds, their production and application as carriers of nucleic acids in cells
AU6571700A (en) Enzymatic synthesis of deoxyribonucleosides
ZA9810915B (en) Optimization of cells for endogenous gene activation.
AU2028601A (en) Arginine-enriched medium composition used for mass-producing recombinant proteinin animal cell culture
AU2002246422A1 (en) Cell culture plate and system using the same
AU7577600A (en) Delivering to eucaryotic cells bacterial proteins that are secreted via type iiisecretion systems
AU2001227142A1 (en) Method for increasing survival rate of cells in animal cell culture under hypoxia condition
WO1998020146A3 (en) Stabilized transient gene expression
CA2151123A1 (en) Cells with altered betaine catabolism, their preparation and their use, in particular for producing metabolites or enzymes
AU8827998A (en) Porcine totipotent cells and method for long-term culture
GB2353798A (en) Regulated expression of PKC and/or SRB1/PSA1 in yeast
HK1052029A1 (en) Method for increasing the yield of recombinant proteins in microbial fermentation processes.

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 97180186.X

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL

WWE Wipo information: entry into national phase

Ref document number: 09093449

Country of ref document: US

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
CFP Corrected version of a pamphlet front page

Free format text: ADD INID NUMBER (63) "RELATED BY CONTINUATION (CON) OR CONTINUATION-IN-PART (CIP) TO EARLIER APPLICATION" WHICH WAS INADVERTENTLY OMITTED FROM THE FRONT PAGE

ENP Entry into the national phase

Ref document number: 1998 521611

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2270137

Country of ref document: CA

Ref document number: 2270137

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1997946432

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 51601/98

Country of ref document: AU

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1997946432

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 51601/98

Country of ref document: AU

WWW Wipo information: withdrawn in national office

Ref document number: 1997946432

Country of ref document: EP